神經內分泌腫瘤治療市場：依藥物類別、適應症、通路和地區分類

Neuroendocrine Tumor Treatment Market, By Drug Class, By Indication, By Distribution Channel, and By Region

出版日期: 2026年04月28日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，神經內分泌腫瘤治療市場規模將達 38.8 億美元，到 2033 年將達到 60 億美元。預計 2026 年至 2033 年的複合年成長率將達到 6.4%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	38.8億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	6.40%	2033年市場規模預測：	60億美元

神經內分泌腫瘤（NETs）是由起源於各種內分泌腺或神經系統細胞的腫瘤細胞異常增殖引起的。雖然大多數NETs是良性的，但有些會發展成惡性腫瘤，並有可能最終發展成癌症。神經內分泌腫瘤通常首先發生於腸道，這類腫瘤通常被稱為類癌。胰臟是NETs發生率第二高的器官。目前，許多臨床試驗正在進行中，旨在開發治療成人胰臟神經內分泌腫瘤的新療法和藥物。

市場動態

胃腸道和肺部神經內分泌腫瘤（NETs）發生率的上升是預計在預測期內推動全球神經內分泌腫瘤治療市場成長的主要因素。例如，根據美國臨床腫瘤學會（ASCO）2019年發布的數據，美國每年約有12,000人被診斷出患有NETs。目前，約有17萬人患有NETs。小腸NETs的五年存活率為86.2%，胃NETs為82.7%，結腸NETs為67.4%。除胃腸道和肺部神經內分泌腫瘤（NETs）外，其他影響NETs的因素還包括腦下垂體和甲狀腺的荷爾蒙失衡。預計北美和歐洲對各種影像技術的需求不斷成長，也將推動全球市場在預測期內的成長。此外，藥物組合的擴展和能夠抑制荷爾蒙過度產生的新產品的開發，預計也將推動全球神經內分泌腫瘤治療市場在預測期內的成長。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、區域前景以及主要參與者採取的競爭策略。
本研究根據以下參數對全球神經內分泌腫瘤治療市場的主要參與者進行了分析：公司概況、財務表現、產品系列、地理企業發展、分銷策略、關鍵發展和策略以及未來計劃。
本報告提供的見解將使企業負責人和經營團隊能夠就未來的產品發布、終端用戶升級、市場擴張和行銷策略做出明智的決策。
這份「全球神經內分泌腫瘤治療市場」報告旨在為該行業的經銷商提供服務，包括神經內分泌腫瘤治療市場的投資者、製藥和產品製造商、分銷商和相關人員、研究和諮詢公司、新參與企業和金融分析師。
在神經內分泌腫瘤治療市場分析中使用的各種策略矩陣為相關人員提供了做出適當策略決策的關鍵資訊。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

公司簡介
- Pfizer Inc.
- Novartis AG
- Ispen
- Advanced Accelerator Applications
- Tarveda Therapeutics
- Progenics Pharmaceuticals, Inc.
- Hutchison Medipharma Limited
- Dauntless Pharmaceuticals Inc.
- Exelixis, Inc.
分析師意見

第9章

參考
調查方法

簡介目錄

Product Code: CMI129

Neuroendocrine Tumor Treatment Market is estimated to be valued at USD 3.88 Bn in 2026 and is expected to reach USD 6.00 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.4% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 3.88 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	6.40%	2033 Value Projection:	USD 6.00 Bn

Neuroendocrine tumors (NETs) result from the abnormal growth of neoplasms that originate from cells of various endocrine glands and nervous systems. Though most of these are benign, some tend to become malignant and may turn cancerous in the long term. Neuroendocrine tumors are generally infected initially in intestine, which are often known as carcinoid tumors. Pancreas is the second most prime organ in the body, where growth of NET is common. There are number of clinical trials are ongoing to develop the novel therapy or drugs for the treatment of the pancreatic neuroendocrine tumors in adult patients.

Market Dynamics

The rising incidence of GI and lung neuroendocrine tumors is a key factor that is expected to fuel growth of the global neuroendocrine tumor treatment market over the forecast period. For instance, according to data published in American Society of Clinical Oncology (ASCO) in 2019, estimated 12,000 people in the U.S. are diagnosed with a NET, each year. And around 170,000 people are living currently with NET. The 5-year survival for NET of the small intestine was 86.2%, 82.7% for stomach, and 67.4% for colon. Apart from GI and Lung Neuroendocrine, there are other factors, which influence NET include hormonal imbalance at pituitsary gland and thyroid gland. The rising demand for various imagining techniques in North America and Europe is expected to fuel growth of the global market over the forecast period. Drug portfolio expansion and development of new products that can inhibit excess hormone production are some of the other factors that are expected to augment growth of the global neuroendocrine tumor treatment market over the forecast period.

Key features of the study:

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global neuroendocrine tumor treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
Key companies covered as a part of this study include Pfizer Inc, Novartis AG, Ispen, Advanced Accelerator Applications, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., Hutchison Medipharma Limited, Dauntless Pharmaceuticals Inc., and Exelixis, Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, end user upgrades, market expansion, and marketing tactics
The global neuroendocrine tumor treatment market report caters to various stakeholders in this industry, including investors, drug/product manufacturers, distributors and suppliers for neuroendocrine tumor treatment market, research and consulting firms, new entrants, and financial analysts
Various strategy matrices used in analyzing the neuroendocrine tumor treatment market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation:

Global Neuroendocrine Tumor Treatment Market, By Treatment Type (Revenue, USD Bn, 2021 - 2033)
Somatostatin Analogues (SSAs)
- Octreotide
- Lanreotide
- Others
Targeted Therapy
Chemotherapy
Others
Global Neuroendocrine Tumor Treatment Market, By Indication (Revenue, USD Bn, 2021 - 2033)
Gastrointestinal NET
Lung NET
Pancreatic NET
Other NET
Global Neuroendocrine Tumor Treatment Market, By End User (Revenue, USD Bn, 2021 - 2033)
Hospitals
Oncology Centers
Others
Global Neuroendocrine Tumor Treatment Market, By Region (Revenue, USD Bn, 2021 - 2033)
North America
- By Treatment Type:
  - Somatostatin Analogues (SSAs)
  - Targeted Therapy
  - Chemotherapy
  - Others
- By Indication:
  - Gastrointestinal NET
  - Lung NET
  - Pancreatic NET
  - Other NET
- By End User
  - Hospitals
  - Oncology Centers
  - Others
- By Country:
  - U.S.
  - Canada
Europe
- By Treatment Type:
  - Somatostatin Analogues (SSAs)
  - Targeted Therapy
  - Chemotherapy
  - Others
- By Indication:
  - Gastrointestinal NET
  - Lung NET
  - Pancreatic NET
  - Other NET
- By End User
  - Hospitals
  - Oncology Centers
  - Others
- By Country:
  - U.K.
  - Germany
  - Italy
  - Spain
  - France
  - Russia
  - Rest of Europe
Asia Pacific
- By Treatment Type:
  - Somatostatin Analogues (SSAs)
  - Targeted Therapy
  - Chemotherapy
  - Others
- By Indication:
  - Gastrointestinal NET
  - Lung NET
  - Pancreatic NET
  - Other NET
- By End User
  - Hospitals
  - Oncology Centers
  - Others
- By Country:
  - Australia
  - India
  - China
  - Japan
  - ASEAN
  - South Korea
  - Rest of Asia Pacific
Latin America
- By Treatment Type:
  - Somatostatin Analogues (SSAs)
  - Targeted Therapy
  - Chemotherapy
  - Others
- By Indication:
  - Gastrointestinal NET
  - Lung NET
  - Pancreatic NET
  - Other NET
- By End User
  - Hospitals
  - Oncology Centers
  - Others
- By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- By Treatment Type:
  - Somatostatin Analogues (SSAs)
  - Targeted Therapy
  - Chemotherapy
  - Others
- By Indication:
  - Gastrointestinal NET
  - Lung NET
  - Pancreatic NET
  - Other NET
- By End User
  - Hospitals
  - Oncology Centers
  - Others
- By Country:
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Treatment Type:
  - Somatostatin Analogues (SSAs)
  - Targeted Therapy
  - Chemotherapy
  - Others
- By Indication:
  - Gastrointestinal NET
  - Lung NET
  - Pancreatic NET
  - Other NET
- By End User
  - Hospitals
  - Oncology Centers
  - Others
- By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
Pfizer Inc*
- Company Overview
- Drug Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Future Plans
Novartis AG
Ispen
Advanced Accelerator Applications
Tarveda Therapeutics
Progenics Pharmaceuticals, Inc.
Hutchison Medipharma Limited
Dauntless Pharmaceuticals Inc.
Exelixis, Inc.

"*" marked represents similar segmentation in other categories in the respective section

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunities
Recent Trends
Recent Launches and Approvals
Mergers, Acquisitions, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis
PORTER's Analysis

4. Global Neuroendocrine Tumor Treatment Market, By Drug Class, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Somatostatin Analogs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends

5. Global Neuroendocrine Tumor Treatment Market, By Indication, 2021- 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Gastrointestinal NET
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
Lung NET
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
Pancreatic NET
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends

6. Global Neuroendocrine Tumor Treatment Market, By Distribution Channel, 2021- 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Bn)
- Segment Trends

7. Global Neuroendocrine Tumor Treatment Market, By Region, 2021-2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 -2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 -2033, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Company Profiles
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novartis AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Ispen
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Advanced Accelerator Applications
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Tarveda Therapeutics
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Progenics Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Hutchison Medipharma Limited
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Dauntless Pharmaceuticals Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Exelixis, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
Analysts' Views